Track Record

Over the past 35 years, Dr. Christine Boers-Doets has provided key stakeholders in the cancer medication chain, like pharma & biotech, regulatory authorities, insurance, healthcare providers, patients and their support system, turnaround strategies on how to turn adverse events into favorable events. Operating at the forefront of systemic cancer treatment, these key stakeholders often experience lack of scientifically proven and practical strategies how to manage adverse events effectively. Inherently, the unresolved adverse events limit the outcome of the lifesaving and life prolonging anticancer treatments. By applying Dr. Christine Boers-Doets's expertise, knowledge and experience, by leveraging the global networks and by supporting  stakeholders in making congruent strategic choices, Dr. Boers-Doets has succeeded in building a robust adverse event turnaround track record.

The overview below shows a selection of Dr. Christine Boers-Doets's clients.

It highlights some of the most noteworthy projects that have cemented her reputation.

By clicking on the logo, you can read details of some of the major milestones in Dr. Christine's history.

BOEHRINGER INGELHEIM


BRISTOL-MYERS SQUIBB


EUSA PHARMA



GLAXOSMITHKLINE

HELSINN

Lilly


LIFESTREAM PHARMA

MERCK


NORDIC PHARMA

NOVARTIS

PFIZER

SANOFI AVENTIS



TAKEDA



Interested in working with Dr. Christine too?